Immunotherapy is a promising new cancer treatment approach. In order to develop effective precision immunotherapies, it is important to identify immune checkpoint targets and the types and locations of immune cells in the tumor microenvironment; e.g., B cells, T cells, others.

The MultiOmyx Tumor Infiltrating Lymphocyte Panel provides the ideal solution: Quantitative analytical results from every cell on your single FFPE slide.

• Comprehensive immune profiling on a single FFPE slide Tissue samples are precious. Unlike IHC assays, which must be performed on serial tissue sections, the MultiOmyx Tumor Infiltrating Lymphocyte Panel evaluates 12 key markers on a single slide.

• Unambiguous individual cell phenotyping The MultiOmyx Tumor Infiltrating Lymphocyte Panel definitively differentiates cell phenotypes and characterizes immune activation and suppression in relation to tumor and stromal regions.

• Advanced bio-image informatics Analysis algorithms provide quantitative expression, co-expression, and co-localization of markers.

• Rigorous quality management system The MultiOmyx Tumor Infiltrating Lymphocyte Panel is offered by NeoGenomics, which is CAP accredited and CLIA certified. Quality management overseen by our dedicated pathologist and Medical Director.

12 cancer immune markers on a single FFPE slide. Provides quantitative analytical results from every cell.

Figure courtesy of Dr. Luster, Cancer Immunol Res; 2(12); 1125-31. 2014 AACR

Comprehensive immune profilingEvaluate 12 key markers on a single slide. Immune markers shown: CD4 (green), CD8 (red), PD-L1 (magenta), CD68 (cyan), pan-CK (yellow).

IF Color Blends

Unambiguous individual cell phenotypingDifferentiates cell phenotypes and characterizes immune activation and suppression in relation to tumor and stromal regions.

Classification Color Blends

CD3 T cell

CD4 TH (helper)

CD8 TC (cytotoxic)

CD20 B cell

CD68 Macrophage

CD56 NK cell

CD45RO Memory T cell

PD-L1 PD1 Ligand

PD1 Inhibit T cell activation

CTLA-4 Inhibit T cell activation

FOXP3 Treg

pan-CK Epithelial Cell

MultiOmyx

MultiOmyx™ Tumor Infiltrating Lymphocyte Panel Comprehensive Immunophenotyping from a Single Slide

Customer will receive a report summarizing cell counts, percentage, tumor and stroma, and density tumor for the sample

For additional information and ordering, please contact 800.720.4363 or seq.sales@neogenomics.com

In addition, a data package will accompany the report including:

• Cell count data in common spreadsheet format → Tab-delimited text files

• Registered, normalized AF removed IF images → One per marker per ROI

• Image QC mask images → One per marker per ROI

• Positive-cell masks → One per marker per ROI

• Concatenated multiple sample data

Expression PhenotypeEpithelial/Tumor

Cell Count = 23,543Non-Epithelial/Stromal

Cell Count = 35,316Total

Cell Count = 58,859

Count % Count % Count %

CD3+ T 1178 5.0 4712 13.3 5890 10.0

CD4+ CD4+ 346 1.5 1384 3.9 1730 2.9

CD8+ CD8+ 676 2.9 2704 7.7 3380 5.7

Remaining 9 single biomarkers

••••

••••

••••

••••

••••

••••

••••

CD3+CD4+ T helper 346 1.5 1384 3.9 1730 2.9

CD3+CD4+FoxP3+ T regulatory 148 0.6 592 1.7 740 1.3

CD3+CD4+FoxP3+PD-L1+ Immune modulation - - - - < 5 -

CD3+CD4+CD45RO+ Memory T helper 234 1.0 936 2.7 1170 2.0

CD3+CD4+PD1+ Immune modulation 48 0.2 192 0.5 240 0.4

CD3+CD4+CTLA-4+ Immune modulation 22 0.1 88 0.2 110 0.2

CD3+CD8+ T cytotoxic 666 2.8 2664 7.5 3330 5.7

CD3+CD8+CD45RO+ Memory T cytotoxic 516 2.2 2064 5.8 2580 4.4

CD3+CD8+PD1+ Anergic T cytotoxic 228 1.0 912 2.6 1140 1.9

CD3+CD8+CTLA-4+ Immune modulation - - - - < 5 -

CD3-CD68+ Macrophage 1312 5.6 5248 14.9 6560 11.1

CD3-CD68+PD-L1+ Immune modulation 64 0.3 256 0.7 320 0.5

CD3-CD20+ B cell 156 0.7 624 1.8 780 1.3

CD3-CD20+PD-L1+ Immune modulation - - - - < 5 -

CD3-CD56+ NK cell 1536 6.5 6144 17.4 7680 13.0

CD3-CD8+CD56+ NK-T - - - - < 5 -

PanCK+PD-L1+ Immune modulation - - - - < 5 -

*For research use only — Validation pending

Indi

vidu

al M

arke

rM

ultip

le M

arke

rs C

o-Ex

pres

sion

31 ColumbiaAliso Viejo, CA 92656 Phone: 800.720.4363/Fax: 949.425.5865 neogenomics.com© 2017 NeoGenomics Laboratories, Inc. All Rights Reserved.MultiOmyx is a registered trademark of NeoGenomics Laboratories, Inc., which holds a license from GE Healthcare BioSciences Corp.Rev. 032417